Drug Profile
Research programme: AMP kinase stimulants - Rigel Pharmaceuticals
Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Cancer; Musculoskeletal disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA (PO)
- 14 Apr 2016 Preclinical trials in Cancer in USA (PO) before April 2016